Abstract P070 – Table 1. Treatment satisfaction and acceptance of ISRs through week 152.
Outcome, ITT‐E	Q8W without prior CAB+RPV exposure (n = 319)	Q4W without prior CAB+RPV exposure (n = 323)	Adjusted difference Q8W to Q4W	p‐value for adjusted difference	Already receiving CAB+RPV Q8W (n = 191)	Already receiving CAB+RPV Q4W (n = 193)b	Adjusted difference Q8W to Q4W	p‐value for adjusted difference
Baseline total HIVTSQs score,a mean (SD)	57.7 (9.2)	56.7 (9.3)	N/A	N/A	62.2 (5.4)	62.0 (6.7)	N/A	N/A
Adjusted mean change from baseline in total HIVTSQs score by visit (95% CI adjusted mean): week 24	5.1 (4.4 to 5.8)	4.0 (3.3 to 4.7)	1.1	0.036	0.6 (0.0 to 1.2)	0.5 (‐0.1 to 1.1)	0.1	0.875
Adjusted mean change from baseline in total HIVTSQs score by visit (95% CI adjusted mean): week 48	4.9 (4.0 to 5.7)	3.1 (2.3 to 4.0)	1.7	0.004	0.4 (‐0.3 to 1.2)	0.0 (‐0.7 to 0.7)	0.5	0.351
Adjusted mean change from baseline in total HIVTSQs score by visit (95% CI adjusted mean): week 152	5.0 (4.2 to 5.8)	3.2 (2.4 to 4.1)	1.8	0.004	0.4 (‐0.4 to 1.2)	0.2 (‐0.6 to 0.9)	0.3	0.642
	Q8W (N = 522)	p‐value for week 24/48/152 vs week 8			Q4W (N = 523)	p‐value for week 24/48/152 vs week 8
Acceptance of ISRs (PIN),c mean (SD): week 8	1.9 (0.9)				1.9 (0.9)
Acceptance of ISRs (PIN),c mean (SD): week 24	1.8 (0.8)	0.004			1.8 (0.8)	0.002
Acceptance of ISRs (PIN),c mean (SD): week 48	1.7 (0.9)	<0.001			1.7 (0.9)	<0.001
Acceptance of ISRs (PIN),c mean (SD): week 152	1.7 (0.8)	<0.001			1.7 (0.8)	0.002

CAB, cabotegravir; HIVTSQs, HIV Treatment Satisfaction Questionnaire status version; ISR, injection site reaction; ITT‐E, intention‐to‐treat exposed; LA, long‐acting; N/A, not applicable; PIN, Perception of Injection; Q4W, every 4 weeks; Q8W, every 8 weeks; RPV, rilpivirine; SD, standard deviation; W, week.

^aScores can range from 0 (minimum; very dissatisfied) to 66 (maximum; very satisfied);

^bW24, n = 193; W48, n = 194; W152, n = 194;

^cscores can range from 1 (totally acceptable) to 5 (not at all acceptable).